FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Carr

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Phenomena

Permeability

Living Beings

Physiology

Procedures

Co-author Network

Publications

TOP 3
Jonathan M Miller; Gregory K Webster; Avital Beig; Robert A Carr; Arik Dahan
The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Jonathan M Miller; Brian J Krieg; Gregory E Amidon; Gordon L Amidon; Avital Beig; Thomas B Borchardt; Robert A Carr; Arik Dahan
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Chih-Liang Chin; Robert A Carr; Daniel Adolfo Llano; Olivier Barret; Hongyu Xu; Jeffrey Batis; Andrei O Koren; John P Seibyl; Kennan Marsh; Gilles Tamagnan; Michael W Decker; Mark Day; Gerard B Fox
Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Carr (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jonathan M Miller; Gregory K Webster; Avital Beig; Robert A Carr; Arik Dahan
The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Molecular pharmaceutics 2012;9(3):581-90.
2011: Jonathan M Miller; Brian J Krieg; Gregory E Amidon; Gordon L Amidon; Avital Beig; Thomas B Borchardt; Robert A Carr; Arik Dahan
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Molecular pharmaceutics 2011;8(5):1848-56.
2011: Chih-Liang Chin; Robert A Carr; Daniel Adolfo Llano; Olivier Barret; Hongyu Xu; Jeffrey Batis; Andrei O Koren; John P Seibyl; Kennan Marsh; Gilles Tamagnan; Michael W Decker; Mark Day; Gerard B Fox
Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089.
The Journal of pharmacology and experimental therapeutics 2011;336(3):716-23.
2010: Yi Gao; John M Lipari; Julie K Spence; Teresa M Turner; Weili W Wang; Robert A Carr; Jonathan M Miller
A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
Molecular pharmaceutics 2010;7(5):1516-26.
2007: Hao Xiong; Robert A Carr; Charles S Locke; David A Katz; Ramanuj Achari; Thao T Doan; Perry Wang; James R Jankowski; Darryl J Sleep
Dual effects of rifampin on the pharmacokinetics of atrasentan.
Journal of clinical pharmacology 2007;47(4):423-9.
2006: Jourik A Gietema; Ronald Hoekstra; Filip De Vos; D R A Uges; Ate van der Gaast; H J M Groen; W J Loos; R A Knight; Robert A Carr; Rod A Humerickhouse; Ferry A L M Eskens
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1320-7.
2006: Ronald Hoekstra; Filip De Vos; Ferry A L M Eskens; E G E de Vries; D R A Uges; R Knight; Robert A Carr; Rod A Humerickhouse; Jaap Verweij; Jourik A Gietema
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
European journal of cancer (Oxford, England : 1990) 2006;42(4):467-72.
2006: Robert A Carr; Amy K André; Ping Chen; Brian A Grabowski; min chang; Charles S Locke; Laura A Williams; Mario Chojkier
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar).
Nephron. Clinical practice 2006;103(3):c100-5.
2005: Ronald Hoekstra; Filip De Vos; Ferry A L M Eskens; Jourik A Gietema; Ate van der Gaast; Harry J M Groen; Raymond A Knight; Robert A Carr; Rod A Humerickhouse; Jaap Verweij; Elisabeth G E de Vries
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5188-97.
2004: Christopher W Ryan; Nicholas J Vogelzang; Everett E Vokes; Hedy L Kindler; Samir D Undevia; Rod A Humerickhouse; Amy K André; Qiang Wang; Robert A Carr; Mark J Ratain
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4406-11.
2003: Bernard A Zonnenberg; Gerard Groenewegen; Todd J Janus; Terri W Leahy; Rod A Humerickhouse; Jeffrey D Isaacson; Robert A Carr; Emile E Voest
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2965-72.
2002: Michael A Carducci; Joel B Nelson; M Kathy Bowling; Theresa Rogers; Mario A Eisenberger; Victoria Sinibaldi; Ross C Donehower; Terri L Leahy; Robert A Carr; Jeffrey D Isaacson; Todd J Janus; Amy Andre; Balakrishna S Hosmane; Robert J Padley
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2171-80.
1998: Robert A Carr; A Edmonds; H Shi; Charles S Locke; Linda E Gustavson; J C Craft; S I Harris; R Palmer
Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.
Antimicrobial agents and chemotherapy 1998;42(5):1176-80.